Glaukos (NYSE:GKOS) has been given a $48.00 price objective by investment analysts at Cantor Fitzgerald in a report released on Wednesday, January 10th. The brokerage currently has a “buy” rating on the medical instruments supplier’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 60.48% from the stock’s previous close.
Several other analysts also recently issued reports on GKOS. BMO Capital Markets lowered their price target on Glaukos from $45.00 to $40.00 and set an “outperform” rating for the company in a report on Wednesday, November 8th. BidaskClub downgraded Glaukos from a “buy” rating to a “hold” rating in a research note on Monday, September 18th. Stephens restated a “buy” rating and set a $47.00 target price on shares of Glaukos in a research note on Friday, September 15th. Zacks Investment Research raised shares of Glaukos from a “sell” rating to a “hold” rating in a research report on Monday, November 13th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $38.00 price target on shares of Glaukos in a research report on Friday, September 15th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $44.86.
Glaukos (NYSE GKOS) traded down $0.24 during mid-day trading on Wednesday, reaching $29.91. The company had a trading volume of 268,346 shares, compared to its average volume of 468,785. Glaukos has a 12-month low of $23.08 and a 12-month high of $52.49. The stock has a market cap of $1,030.00 and a price-to-earnings ratio of -997.00.
Glaukos (NYSE:GKOS) last released its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.06. The business had revenue of $40.41 million during the quarter, compared to the consensus estimate of $38.69 million. Glaukos had a positive return on equity of 3.50% and a negative net margin of 0.64%. The business’s revenue for the quarter was up 36.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.03 EPS. equities research analysts anticipate that Glaukos will post -0.03 EPS for the current fiscal year.
In other news, CFO Joseph E. Gilliam purchased 2,100 shares of the company’s stock in a transaction on Wednesday, November 22nd. The shares were bought at an average price of $23.84 per share, for a total transaction of $50,064.00. Following the completion of the purchase, the chief financial officer now owns 102,100 shares of the company’s stock, valued at $2,434,064. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 16.40% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. California Public Employees Retirement System increased its stake in shares of Glaukos by 10.5% during the second quarter. California Public Employees Retirement System now owns 8,400 shares of the medical instruments supplier’s stock valued at $348,000 after acquiring an additional 800 shares during the period. PNC Financial Services Group Inc. grew its position in Glaukos by 1.4% in the second quarter. PNC Financial Services Group Inc. now owns 70,313 shares of the medical instruments supplier’s stock worth $2,915,000 after buying an additional 994 shares during the last quarter. Ameritas Investment Partners Inc. grew its position in Glaukos by 93.1% in the second quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock worth $104,000 after buying an additional 1,212 shares during the last quarter. GSA Capital Partners LLP grew its position in Glaukos by 3.7% in the second quarter. GSA Capital Partners LLP now owns 35,080 shares of the medical instruments supplier’s stock worth $1,455,000 after buying an additional 1,237 shares during the last quarter. Finally, Navellier & Associates Inc grew its position in Glaukos by 4.9% in the second quarter. Navellier & Associates Inc now owns 33,307 shares of the medical instruments supplier’s stock worth $1,381,000 after buying an additional 1,567 shares during the last quarter. Institutional investors and hedge funds own 98.95% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Glaukos (NYSE:GKOS) Given a $48.00 Price Target at Cantor Fitzgerald” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/03/glaukos-gkos-pt-set-at-48-00-by-cantor-fitzgerald.html.
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.